T cell dynamics with neoadjuvant immunotherapy in head and neck cancer

M Zhao, JD Schoenfeld, AM Egloff, GJ Hanna… - Nature Reviews …, 2024 - nature.com
Immune-checkpoint inhibitors (ICIs) are being tested as neoadjuvant therapies in various
solid tumours, including in patients with head and neck squamous cell carcinoma (HNSCC) …

Convergence of evolving artificial intelligence and machine learning techniques in precision oncology

E Fountzilas, T Pearce, MA Baysal, A Chakraborty… - npj Digital …, 2025 - nature.com
The confluence of new technologies with artificial intelligence (AI) and machine learning
(ML) analytical techniques is rapidly advancing the field of precision oncology, promising to …

[HTML][HTML] Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach

A Zotta, ML Marciano, F Sabbatino, A Ottaiano… - …, 2024 - pmc.ncbi.nlm.nih.gov
Checkpoint inhibitors (ICIs) have demonstrated substantial efficacy in the treatment of
numerous solid tumors, including head and neck cancer. Their inclusion in the therapeutic …

Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM …

SW Huang, W Jiang, S Xu, Y Zhang, J Du… - … and Targeted Therapy, 2024 - nature.com
The identification of predictors for immunotherapy is often hampered by the absence of
control groups in many studies, making it difficult to distinguish between prognostic and …